KOSDAQBiotech & Pharma234690

GC WellBeing

₩8,880▲ 2.42%2026-11-18 close
Market Cap
₩159.5B
Turnover
₩1.8B
Volume
210K
Shares out.
18M
PER
30.8×
PBR
1.3×
EPS
₩286
Dividend Yield
1.59%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩140 per share · Prices as of the 2026-11-18 close

01

Report overview

Placenta injection growth lifts earnings

Rising sales of the placenta injection Rainek and nutrition injections have lifted GC WellBeing's operating margin from 7.7% in 2022 to 10.5% in 2025, while quarterly net profit has swung sharply and the debt ratio has risen.

  1. 1

    Sales reached KRW 164.7 billion in 2025, up 23.1% from the prior year, and have risen for three consecutive years from 2023.

  2. 2

    The operating margin climbed from 7.7% in 2022 to 9.7% in 2024 and 10.5% in 2025.

  3. 3

    Third-quarter 2026 operating profit rose 39.1% year on year to KRW 7.25 billion, while profit attributable to controlling shareholders fell 10.2% to KRW 3.34 billion.

  4. 4

    The first quarter of 2026 swung to a controlling-shareholder net loss of KRW 3.05 billion, and the second quarter returned to a profit of KRW 3.97 billion.

  5. 5

    The debt ratio rose to 97.2% at the end of 2025 from 53.9% a year earlier, and derivative valuation gains and losses tied to convertible bonds remain a source of net profit volatility.

02

Business structure

GC WellBeing is built on two pillars: specialty pharmaceuticals and medical aesthetics. In 2024 it spun off its general health-food business into a subsidiary through a physical split, and it has since shifted toward prescription drugs and aesthetics.

According to a report based on the second quarter of 2025, the health-food share of sales fell from 32.8% in 2020 to 9.7%, while the share from specialty drugs and aesthetics rose from 64.5% to 88.5%.

Its flagship placenta injection Rainek is reported to hold about 77% of the domestic market, and cumulative shipments passed 100 million ampoules in July 2026.

The company obtained approval for a high-dose intravenous drip regimen to broaden how the product is administered, and it is pushing to widen prescription access through co-promotion with Boryung. Nutrition injections are also cited as a strategic product line.

In aesthetics, the company has expanded into botulinum toxin, fillers and ECM-based skin boosters, combining a clinic network with consumer-facing B2C marketing. The toxin product Inibo was developed by affiliate Inibio, and it has received Chinese marketing approval as the company prepares a commercial launch there.

The largest shareholder changed from the operating company GC to the holding company GC Holdings, which holds a 34.47% stake. Competitively, Rainek is reported as a domestic leader in placenta injections, while the toxin and filler markets are contested by many domestic and foreign companies.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩42.3B₩5.2B12.3%
2025Q4₩48.7B₩2.9B5.9%
2026Q1₩49.1B₩4.8B9.8%
2026Q2₩52.1B₩4.6B8.9%
2026Q3₩52.1B₩7.3B13.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩109.7B₩8.4B₩8B7.7%8.3%56.2%
2023₩120.5B₩10.5B₩6.7B8.7%6.7%56.0%
2024₩133.8B₩13B₩7.1B9.7%6.7%53.9%
2025₩164.7B₩17.3B₩10B10.5%8.9%97.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On an annual basis, sales rose from KRW 109.7 billion in 2022 to KRW 120.5 billion in 2023, KRW 133.8 billion in 2024 and KRW 164.7 billion in 2025. Growth was 9.8% in 2023 and 11.0% in 2024, then accelerated to 23.1% in 2025.

Operating profit rose from KRW 8.4 billion in 2022 to KRW 10.5 billion in 2023 (up 24.6%), KRW 13 billion in 2024 (up 24.0%) and KRW 17.3 billion in 2025 (up 33.4%). The operating margin climbed every year, from 7.7% in 2022 to 8.7% in 2023, 9.7% in 2024 and 10.5% in 2025.

Profit attributable to controlling shareholders fell 15.7% to KRW 6.75 billion in 2023 after KRW 8 billion in 2022, then recovered to KRW 7.07 billion in 2024 and KRW 10 billion in 2025 (up 41.6%). Net profit including non-controlling interests was reported at the same amounts in each of these years.

Operating cash flow went from KRW 1.82 billion in 2022 to negative KRW 1.03 billion in 2023, then turned to KRW 13.7 billion in 2024 and KRW 5.73 billion in 2025. At the end of 2025, total equity was KRW 112.7 billion and total liabilities were KRW 109.5 billion, so the debt ratio reached 97.2%, up from 53.9% in 2024.

On a quarterly basis, sales were KRW 42.3 billion in the third quarter of 2025 and rose to KRW 48.7 billion in the fourth quarter, when operating profit fell 44.9% sequentially to KRW 2.87 billion.

Sales were KRW 49.1 billion in the first quarter of 2026 and KRW 52.1 billion in both the second and third quarters, while operating profit was KRW 4.82 billion, KRW 4.63 billion and KRW 7.25 billion.

The first quarter of 2026 showed operating profit rising while the controlling-shareholder result was a loss of KRW 3.05 billion, a wide gap that points to items below the operating line.

A derivative valuation loss on convertible bonds was disclosed in May 2026, which makes below-the-line items the first place to examine.

On a cumulative basis through the third quarter of 2026, sales grew 32.2% to KRW 153.3 billion and operating profit grew 15.8% to KRW 16.7 billion, so sales growth outpaced profit growth.

Company statements attribute the improvement in the first half of 2026 partly to better cost ratios from higher utilization at its Eumseong plant.

05

Industry analysis

The placenta injection Rainek is reported as a domestic leader, and the company is focused on widening prescription access and administration options for the product.

In China, Rainek has been sold in Hainan under expedited import approval since September 2024, and a 2025 report said sales would expand nationwide from 2026 after registration was completed.

In toxins, affiliate Inibio's Inibo received approvals in Thailand and Peru and has been preparing entry into Brazil and China, and it received Chinese NMPA marketing approval in the third quarter of 2026.

Domestic toxin and filler markets involve many domestic and foreign competitors, so the company is trying to differentiate through its clinic network and B2C marketing.

Health foods have become a shrinking share of sales, and the company separated that business through a physical split to concentrate on specialty drugs and aesthetics.

Compared with Hugel, a listed toxin specialist in the same industry, GC WellBeing's profile combines placenta and nutrition injections with its toxin business rather than relying on toxins alone.

06

Outlook

The company is concentrating on widening how Rainek is administered and where it is prescribed. It has received approval for a high-dose intravenous drip regimen and is pushing to expand prescription access through co-promotion with Boryung.

The Rainek plan in China began in Hainan and is set to expand nationwide from 2026. In medical aesthetics, the company intends to grow through a commercial launch of Inibo in China and further overseas entry.

In its first-half 2026 results, the company said marketing spending on the skin booster Giselle and the filler Rebonne should be reflected in second-half results as the products settle in the market and sales channels widen.

In its third-quarter 2026 release, the company said cumulative sales growth is widening and it will expand its aesthetics portfolio, B2C marketing and global business. The company has not yet quantified how much revenue the China expansion and Inibo launch will contribute, or when.

The next checkpoint is whether aesthetics marketing costs show up in the operating margin in the 2026 annual results and business report. The first-quarter 2027 results will show whether the wider sales channels for Giselle and Rebonne are converting into revenue.

07

Valuation

PER
30.8×
PBR
1.3×
ROE
4.5%
EPS
₩286
BPS
₩6,613
Dividend per share
₩140

The share price is better read through two lenses, earnings and net assets. Profit attributable to controlling shareholders recovered through 2025 after a dip in 2023, but the first quarter of 2026 swung to a net loss.

Because the combined profit over the last four quarters is KRW 5.11 billion, multiples based on earnings are highly sensitive to quarterly swings in net profit.

Operating profit moved from KRW 17.3 billion in 2025 to KRW 16.7 billion cumulatively through the third quarter of 2026, so the core operating earnings have been comparatively steady.

On a net-asset basis, market capitalization sits above total equity at the end of 2025, which means the shares carry a premium to book value. With the debt ratio at 97.2% and convertible-bond derivative valuation swings in the picture, the quality of earnings deserves a closer look alongside any multiple. Dividend yield moves with the share price, so it should be read together with that price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Growth of the placenta injection Rainek

Rainek's first-half 2026 sales reached KRW 25.5 billion, up about 26% year on year, and cumulative shipments passed 100 million ampoules in July 2026. A high-dose intravenous regimen approval has broadened how the product is given, and co-promotion with Boryung aims to widen prescriptions.

With nationwide expansion in China planned after the Hainan launch, overseas sales could contribute more over time.

Expansion of aesthetics and global products

The toxin Inibo has received Chinese marketing approval and is already sold in Thailand and Peru. The company has widened its line to skin boosters such as Giselle and fillers such as Rebonne and names medical aesthetics as a medium-to-long-term growth engine. Pairing its clinic network with B2C marketing gives it a way to reach consumers directly.

Operating profit–led margin improvement

Operating profit rose from KRW 8.4 billion in 2022 to KRW 17.3 billion in 2025, and the operating margin improved from 7.7% to 10.5% over the same period. Third-quarter 2026 operating profit climbed 39.1% year on year to KRW 7.25 billion. The company said higher utilization at its Eumseong plant improved its cost ratio in the first half of 2026.

09

Bear factors

Volatility in quarterly net profit

Profit attributable to controlling shareholders swung to a loss of KRW 3.05 billion in the first quarter of 2026, returned to a profit of KRW 3.97 billion in the second quarter, and then fell 10.2% year on year to KRW 3.34 billion in the third quarter.

In the fourth quarter of 2025 it dropped 77.2% sequentially to KRW 849 million. Across the last four quarters, the combined total is only KRW 5.11 billion.

Debt ratio and convertible-bond valuation swings

The debt ratio rose to 97.2% at the end of 2025 from 53.9% at the end of 2024. According to a summary of DART filings, a May 2026 disclosure showed a cumulative derivative valuation loss on convertible bonds of KRW 6.12 billion. An April 2026 correction also concerned the exercise of conversion rights.

Burden of aesthetics marketing costs

First-half 2026 operating profit grew only 2.6% year on year, well below the 37.4% sales growth. The company attributed the gap to marketing spending tied to the launch of Giselle and Rebonne. Cumulative operating profit through the third quarter of 2026 rose 15.8%, again below the 32.2% growth in cumulative sales.

10

Risk factors

Regulation and approvals

Placenta-derived injections are human-origin drugs, so manufacturing and quality control requirements are demanding. Nationwide expansion of Rainek in China and the commercial launch of Inibo depend on local approvals and registration, which could slip. Any delay in overseas approvals would push back the timing of overseas revenue plans.

Derivative valuation swings

Derivative valuation gains and losses attached to convertible bonds can move quarterly net profit. Because the direction of these valuations changes with the share price, the gap between operating profit and net profit can widen. Reading quarterly net profit requires separating operating profit from non-operating items.

Ownership restructuring

The largest shareholder changed from the operating company GC to the holding company GC Holdings, and the group's business and funding structure is being reorganized. Holding-company-led M&A or further restructuring has been mentioned, but GC said no specific decision has been made. The direction and pace of the reorganization could change the business strategy.

11

What to watch next

  1. After November 2026 (date not set)

    Progress on nationwide Rainek sales in China and the commercial launch of Inibo. The key check is whether these generate visible revenue.

  2. Around late January 2027

    Preliminary 2026 full-year operating results, based on the January 31, 2024 precedent. This will show fourth-quarter operating profit and the full-year operating margin.

  3. March 2027

    Filing of the 2026 annual business report. As the next regular report, it will cover annual financial statements, the debt structure and the convertible-bond notes.

  4. Around late April 2027

    Preliminary first-quarter 2027 results, based on the April 30, 2025 and May 7, 2026 precedents. The key check is whether profit attributable to controlling shareholders stays positive.

  5. Around late July 2027

    Preliminary second-quarter 2027 results, based on the July 31, 2026 precedent. They will show how far aesthetics marketing costs weigh on the operating margin.

12

Overall view

GC WellBeing has grown sales and operating profit together from 2023 through 2025, driven by specialty drugs including the placenta injection Rainek and nutrition injections.

The health-food share of sales fell from 32.8% in 2020 to 9.7% in the second quarter of 2025, and the business now centers on prescription drugs and aesthetics. The operating margin reached 10.5% in 2025, and cumulative sales and operating profit through the third quarter of 2026 both grew by double digits.

However, profit attributable to controlling shareholders recovered only after a decline in 2023 and posted a net loss in the first quarter of 2026, so quarterly results have been uneven.

The debt ratio stood at 97.2% at the end of 2025, and derivative valuation swings on convertible bonds remain a source of net profit volatility. Marketing spending on the new aesthetics business also held back operating profit growth in the first half of 2026, which deserves attention.

The next checkpoints are the 2026 preliminary annual results, the 2026 business report, and whether Rainek's expansion in China and the Inibo launch show up in revenue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. thevc.kr
  2. etoday.co.kr
  3. weekly.hankooki.com
  4. thevaluenews.co.kr
  5. topdaily.kr
  6. newstomato.com
  7. thebionews.net
  8. eduinfom.com
  9. ngonews.kr
  10. kormedi.com
  11. thefairnews.co.kr
  12. inthenews.co.kr
  13. goinsider.kr
  14. sangsanginib.com
  15. thebionews.net
  16. m.irgo.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis